20 likes | 130 Views
Explore the impacts of SARS-CoV-2 vaccine formulations on DCs at different MOIs, assessing CD86, HLA-DR, CD83, and CCR7R expressions. Investigate the immunological responses and potential for enhancing vaccine efficacy.
E N D
DC AdCCL21-DC MOI 50:1 AdCCL21-DC MOI 100:1 AdCV-DC MOI 50:1 CD86 HLA-DR CD83 CCR7R